Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GCN2iB is an ATP-competitive inhibitor of general control nonderepressible 2 (GCN2) with an IC50 of 2.4 nM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 77.00 | |
5 mg | In stock | $ 178.00 | |
10 mg | In stock | $ 288.00 | |
25 mg | In stock | $ 576.00 | |
50 mg | In stock | $ 825.00 | |
100 mg | In stock | $ 1,130.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 196.00 |
Description | GCN2iB is an ATP-competitive inhibitor of general control nonderepressible 2 (GCN2) with an IC50 of 2.4 nM. |
Targets&IC50 | GCN2:2.4 nM |
In vitro | GCN2iB shows an IC50 value of 2.4 nM for GCN2 and potent cellular activity. In a panel of 468 kinases, only GCN2 shows >99.5% inhibition, and three kinases (MAP2K5, STK10, and ZAK) show >95%inhibition at 1 μM GCN2iB, demonstrating high kinase selectivity. |
In vivo | In the antitumor activity study of the CCRF-CEM xenografts, ASNase or GCN2iB alone does not significantly affect tumor growth.Notably, a combination of ASNase and GCN2iB elicits potent antitumor activity (P=0.0002) with synergistic effects.In MV-4-11 and SU.86.86 xenografts, the robust antitumor activity of the combination of GCN2iB and ASNase is observed with a synergistic effect, respectively.ASNase/GCN2iB-treated tumors do not show significant growth even after drug cessation. |
Molecular Weight | 451.83 |
Formula | C18H12ClF2N5O3S |
CAS No. | 2183470-12-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15 mg/mL (33.20 mM), Sonification is recommended.
H2O: < 0.1 mg/mL (insoluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GCN2iB 2183470-12-2 Autophagy Others inhibit GCN-2iB Inhibitor Eukaryotic Initiation Factor (eIF) inhibitor